These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17724008)

  • 21. Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
    Fadda V; Maratea D; Trippoli S; Messori A
    J Endocrinol Invest; 2015 Feb; 38(2):189-92. PubMed ID: 25412945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 25. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
    Tadrous M; Wong L; Mamdani MM; Juurlink DN; Krahn MD; Lévesque LE; Cadarette SM
    Osteoporos Int; 2014 Apr; 25(4):1225-35. PubMed ID: 24287510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 35. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
    Bonnick S; Saag KG; Kiel DP; McClung M; Hochberg M; Burnett SM; Sebba A; Kagan R; Chen E; Thompson DE; de Papp AE
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
    Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
    J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
    Lai PS; Chua SS; Chan SP
    J Clin Pharm Ther; 2012 Oct; 37(5):536-43. PubMed ID: 22380577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
    Takada J; Iba K; Imoto K; Yamashita T
    J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
    Tremaine WJ; Khosla S
    Mayo Clin Proc; 2002 Oct; 77(10):1029-30. PubMed ID: 12374246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.